Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The anturane reinfarction trial

S Sherry

    Circulation
    |December 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Sulfinpyrazone (Anturane) reduced cardiac mortality by 32% in post-myocardial infarction patients, primarily by decreasing sudden cardiac death within six months. This finding offers insights into secondary prevention strategies for heart attack survivors.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Accessible and reliable neurometric testing in humans using a smartphone platform.

    Scientific reports·2023
    Same author

    THROMBOEMBOLIC DISORDERS.

    A listing of research in the cardiovascular field·2014
    Same author

    Typhus in lower Bavaria.

    Bulletin of the U.S. Army Medical Department. United States. Army. Medical Department·2010
    Same author

    NCBI genetic resources supporting immunogenetic research.

    Reviews in immunogenetics·2002
    Same author

    A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms.

    Nature·2001
    Same author

    Diabetes mellitus: a frequent factor in liability claims.

    New Jersey medicine : the journal of the Medical Society of New Jersey·1994
    Same journal

    Eugene Braunwald, MD, 1929-2026.

    Circulation·2026
    Same journal

    AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

    Circulation·2026
    Same journal

    Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

    Circulation·2026
    Same journal

    Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

    Circulation·2026
    Same journal

    Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

    Circulation·2026
    Same journal

    Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

    Circulation·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Clinical Pharmacology

    Background:

    • Secondary prevention of cardiac mortality after acute myocardial infarction (MI) is critical.
    • Platelet-active drugs are commonly investigated for their cardiovascular benefits.

    Purpose of the Study:

    • To evaluate the efficacy of sulfinpyrazone (Anturane) in reducing cardiac mortality in patients recently recovered from an acute myocardial infarction.

    Main Methods:

    • A clinical efficacy trial involving 1558 patients, observed for 16 months post-MI.
    • Patients were randomized to receive either sulfinpyrazone (200 mg four times daily) or placebo.
    • Entry criteria focused on a narrow window (25-35 days post-MI) to compare against the natural history of mortality.

    Main Results:

    Related Experiment Videos

  • Sulfinpyrazone showed a 32% reduction in overall cardiac mortality (43 vs. 62 deaths), with borderline statistical significance (p=0.044-0.058).
  • A significant reduction in sudden cardiac death was observed (43% reduction, p=0.023-0.041).
  • The benefit was concentrated in preventing sudden death within the first six months post-MI, with a 74% reduction (p=0.001-0.003).

    • Conclusions:

    • Sulfinpyrazone demonstrated a potential benefit in reducing cardiac mortality, particularly sudden death, in the early high-risk period following myocardial infarction.
    • The drug's effect appears specific to preventing sudden death in the initial months after an MI.